• If you are trying to figure out whether Alignment Healthcare is fairly priced or not, starting with what the current market is implying can help you frame that question clearly.
• The stock recently closed at US$23.61, with returns of 4.9% over 7 days, 20.9% over 30 days, 16.8% year to date and 62.0% over the past year. These figures may influence how investors think about its growth potential and risk.
• Recent news flow around Alignment Healthcare has largely focused on its position in the US healthcare space and how its model fits into a competitive Medicare Advantage market. This provides context for the recent price movements. Coverage has highlighted how investors are watching membership trends and healthcare policy developments closely, which can feed directly into sentiment around the shares.
• On Simply Wall St's valuation checks, Alignment Healthcare currently has a score of 1 out of 6. Next we will look at what different valuation methods say about that pricing and finish by talking about a more complete way to think about valuation beyond a single score.

Alignment Healthcare scores just 1/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: Alignment Healthcare Discounted Cash Flow (DCF) Analysis

A DCF model takes Alignment Healthcare’s expected future cash flows and discounts them back to today using a required rate of return. The idea is to estimate what those future cash flows are worth in today’s dollars.

For Alignment Healthcare, the model uses a 2 Stage Free Cash Flow to Equity approach. The latest twelve month free cash flow is about $132.5 million. Analysts provide explicit forecasts for the next few years, and Simply Wall St then extrapolates further cash flows. For example, projected free cash flow for 2027 is $139.5 million, with a series of estimates running out to 2035 that gradually adjust using modest growth assumptions.

When you add up all of those discounted cash flows, the model arrives at an estimated intrinsic value of about $17.42 per share. Compared with the recent market price of US$23.61, this implies Alignment Healthcare trades at roughly a 35.6% premium to the DCF estimate, so on this cash flow view the shares screen as expensive.

Result: OVERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Alignment Healthcare may be overvalued by 35.6%. Discover 876 undervalued stocks or create your own screener to find better value opportunities.

Approach 2: Alignment Healthcare Price vs Sales

For companies where earnings are not a clean guide, the P/S ratio is often a useful way to think about valuation because it compares the share price to the revenue the business is generating, rather than profits that can swing around.

What investors usually pay on a P/S basis tends to reflect a mix of growth expectations and perceived risk. Higher expected revenue growth or lower perceived risk can support a higher “normal” P/S, while slower growth or higher uncertainty usually justify a lower multiple.

Alignment Healthcare currently trades on a P/S of 1.30x. That sits very close to the broader Healthcare industry average of 1.30x and below the peer group average of 1.95x. Simply Wall St’s Fair Ratio for Alignment Healthcare is 1.19x. This is its proprietary view of what a reasonable P/S might be, after taking into account factors like earnings growth, industry, profit margins, market cap and key risks.

This Fair Ratio goes a step further than simple peer or industry comparisons because it adjusts for the company’s own profile rather than assuming one size fits all. Compared with the actual P/S of 1.30x, the Fair Ratio of 1.19x suggests the shares screen as slightly expensive on this measure.

Result: OVERVALUED

P/S ratios tell one story, but what if the real opportunity lies elsewhere? Discover 1427 companies where insiders are betting big on explosive growth.

Upgrade Your Decision Making: Choose your Alignment Healthcare Narrative

Earlier we mentioned that there is an even better way to understand valuation, so let us introduce you to Narratives. This simply means writing the story you believe about Alignment Healthcare and tying that story directly to your own assumptions for future revenue, earnings, margins and a fair value estimate.

On Simply Wall St, Narratives live in the Community page and give you a clear link from the company’s story to a forecast and then to a fair value. This allows you to easily compare that fair value with the current share price and decide whether the gap is significant enough for you to consider buying or selling.

Because Narratives on the platform are updated when fresh information comes in, such as new earnings or news, your view is not static. It adjusts as the facts change without you needing to rebuild everything from scratch.

For Alignment Healthcare, one investor might see strong long term potential and set a relatively high fair value. Another might focus on competitive pressures in Medicare Advantage and choose a lower fair value. Both can clearly see how their assumptions lead to different numbers and decisions.

Do you think there's more to the story for Alignment Healthcare? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.